Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Cyclically Adjusted Revenue per Share: NT$22.07 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1762 Chunghwa Chemical Synthesis & Biotech Co Ltd TPE:1762
59 GF Score
Price NT$32.60
GF Value NT$39.05
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Chunghwa Chemical Synthesis & Biotech Co Cyclically Adjusted Revenue per Share?

Chunghwa Chemical Synthesis & Biotech Co TPE:1762 +1.24% 59 Cyclically Adjusted Revenue per Share is NT$22.07 as of Dec. 2025. GuruFocus rates TPE:1762 with a GF Score™ of 59/100 and a GF Value™ of NT$39.05 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Chunghwa Chemical Synthesis & Biotech Co's adjusted revenue per share for the three months ended in Dec. 2025 was NT$2.049. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$22.07 for the trailing ten years ended in Dec. 2025.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Chunghwa Chemical Synthesis & Biotech Co was 9.50% per year. The lowest was 3.80% per year. And the median was 7.10% per year.

As of today (2026-08-01), Chunghwa Chemical Synthesis & Biotech Co's current stock price is NT$32.60. Chunghwa Chemical Synthesis & Biotech Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was NT$22.07. Chunghwa Chemical Synthesis & Biotech Co's Cyclically Adjusted PS Ratio of today is 1.48.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Chunghwa Chemical Synthesis & Biotech Co was 4.80. The lowest was 1.08. And the median was 2.73.


Chunghwa Chemical Synthesis & Biotech Co  (TPE:1762) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Chunghwa Chemical Synthesis & Biotech Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=32.60/22.07
=1.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Chunghwa Chemical Synthesis & Biotech Co was 4.80. The lowest was 1.08. And the median was 2.73.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Chunghwa Chemical Synthesis & Biotech Co Cyclically Adjusted Revenue per Share Related Terms


Chunghwa Chemical Synthesis & Biotech Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Chunghwa Chemical Synthesis & Biotech Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chunghwa Chemical Synthesis & Biotech Co Cyclically Adjusted Revenue per Share Chart

Chunghwa Chemical Synthesis & Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.03 19.73 21.31 22.06 22.07

Chunghwa Chemical Synthesis & Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.06 22.26 22.56 22.54 22.07

TPE:1762 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Chunghwa Chemical Synthesis & Biotech Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chunghwa Chemical Synthesis & Biotech Co Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chunghwa Chemical Synthesis & Biotech Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Chunghwa Chemical Synthesis & Biotech Co's Cyclically Adjusted PS Ratio falls into.


TPE:1762
59GF Score
Chunghwa Chemical Synthesis & Biotech Co Ltd TPE:1762
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chunghwa Chemical Synthesis & Biotech Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Chunghwa Chemical Synthesis & Biotech Co's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=2.049/324.0540*324.0540
=2.049

Current CPI (Dec. 2025) = 324.0540.

Chunghwa Chemical Synthesis & Biotech Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 3.417 238.132 4.650
201606 3.825 241.018 5.143
201609 4.309 241.428 5.784
201612 3.867 241.432 5.190
201703 3.510 243.801 4.665
201706 2.523 244.955 3.338
201709 4.636 246.819 6.087
201712 4.365 246.524 5.738
201803 3.536 249.554 4.592
201806 4.232 251.989 5.442
201809 2.295 252.439 2.946
201812 2.904 251.233 3.746
201903 4.392 254.202 5.599
201906 4.038 256.143 5.109
201909 2.809 256.759 3.545
201912 3.514 256.974 4.431
202003 3.940 258.115 4.947
202006 5.047 257.797 6.344
202009 3.639 260.280 4.531
202012 7.024 260.474 8.739
202103 5.395 264.877 6.600
202106 6.410 271.696 7.645
202109 6.489 274.310 7.666
202112 6.427 278.802 7.470
202203 6.753 287.504 7.611
202206 7.444 296.311 8.141
202209 5.942 296.808 6.487
202212 6.890 296.797 7.523
202303 9.787 301.836 10.507
202306 6.757 305.109 7.177
202309 4.298 307.789 4.525
202312 5.873 306.746 6.204
202403 3.227 312.332 3.348
202406 5.908 314.175 6.094
202409 4.649 315.301 4.778
202412 3.692 315.605 3.791
202503 3.444 319.799 3.490
202506 6.183 322.561 6.212
202509 2.793 324.800 2.787
202512 2.049 324.054 2.049

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$22.07 mean?
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) has a Cyclically Adjusted Revenue per Share of NT$22.07 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors.
Is Chunghwa Chemical Synthesis & Biotech Co's Cyclically Adjusted Revenue per Share too high?
Chunghwa Chemical Synthesis & Biotech Co's current Cyclically Adjusted Revenue per Share is NT$22.07. Overall, Chunghwa Chemical Synthesis & Biotech Co has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chunghwa Chemical Synthesis & Biotech Co's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Chunghwa Chemical Synthesis & Biotech Co's Cyclically Adjusted Revenue per Share of NT$22.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. Chunghwa Chemical Synthesis & Biotech Co's current Cyclically Adjusted Revenue per Share is NT$22.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chunghwa Chemical Synthesis & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$39.05, compared to a current price of NT$32.60 — trading 16.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$22.07. Chunghwa Chemical Synthesis & Biotech Co's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Chunghwa Chemical Synthesis & Biotech Co (TPE:1762), the current Cyclically Adjusted Revenue per Share is NT$22.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Overvalued in 2026?

Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co stock appears to be undervalued. The current stock price of NT$32.60 is trading 16.5% below its estimated GF Value™ of NT$39.05. GuruFocus considers Chunghwa Chemical Synthesis & Biotech Co to be Modestly Undervalued.

Key valuation signals for TPE:1762:

  • Cyclically Adjusted Revenue per Share: NT$22.07
  • GF Value™: NT$39.05 vs. price of NT$32.60 (16.5% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the TPE:1762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chunghwa Chemical Synthesis & Biotech Co Business Description

Address No. 1, Dongxing Street, Shulin District, Taipei, TWN
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
59GF Score

Get the complete analysis for TPE:1762

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.60
Price
NT$39.05
GF Value